March #162 : Medicine Chest

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Leading Ladies

Wonder Women




Crystal Clear

Go With the Flow

A Tell-Tale Heart

Going Rogue

Medicine Chest

Shifting the Starting Lines

The Power of Pampering




POZ Q&A: Senator Kirsten Gillibrand

Big Talk in the Big Apple

Faith in Numbers

Tropic Thunder

Are You Positive You’re Negative?




Editor's Letter-March 2010

Your Feedback-March 2010

In Memoriam

GMHC Treatment Issues-March 2010



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

March 2010


Medicine Chest

HIV drug news

Selzentry (maraviroc, an entry inhibitor) is now FDA-approved for people new to HIV meds. Before, it was available only to people who had developed resistance to other meds.

Intelence (etravirine, a non-nuke) has received full FDA approval—but it is still only prescribed for people who’ve already taken at least one previous HIV combo.

Bevirimat (an experimental maturation inhibitor) might not work for the nearly 40 percent of positive people whose HIV has certain resistance mutations. That’s in addition to those with resistance to protease inhibitors (PIs), for whom bevirimat’s power might also be muted. Researchers believe drug-resistance screening might be needed before bevirimat is prescribed.

Lexiva (fosamprenavir, a PI) may raise the risk of heart attack, according to the FDA. The drug’s manufacturer suggests screening people for triglyceride and cholesterol levels before prescribing Lexiva.   

Retrovir (zidovudine, a nuke) can now be given to babies as young as 4 weeks old (before, it was only for infants 6 weeks and up). The FDA has also issued new pediatric dosing guidelines for the drug. For details, search “new dosing Retrovir” at fda.gov.

Search: Selzentry, Intelence, Bevirimat, Lexiva, Retrovir, FDA, resistance, combo, experimental maturation inhibitor, resistance mutations, heart attack, risk, cholosterol, infants


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.